Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Holdings Lifted by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,896 shares of the company's stock after buying an additional 20,204 shares during the period. Schroder Investment Management Group owned approximately 0.25% of Kymera Therapeutics worth $6,444,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Blue Trust Inc. grew its position in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. Harbor Capital Advisors Inc. increased its stake in Kymera Therapeutics by 1.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock worth $1,649,000 after buying an additional 684 shares during the period. KBC Group NV lifted its holdings in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Kymera Therapeutics by 8.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock valued at $534,000 after buying an additional 915 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Kymera Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company's stock valued at $552,000 after acquiring an additional 1,311 shares in the last quarter.

Remove Ads

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $2.90 during trading on Wednesday, hitting $23.95. 1,790,274 shares of the stock were exchanged, compared to its average volume of 543,247. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The stock's fifty day moving average is $32.23 and its 200 day moving average is $40.16. The stock has a market cap of $1.56 billion, a PE ratio of -10.24 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

KYMR has been the subject of a number of analyst reports. Citigroup began coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target for the company. Leerink Partners reissued an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Stephens reissued an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, BTIG Research began coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $60.00 target price on the stock. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Insider Activity at Kymera Therapeutics

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,659 shares of company stock worth $324,567 in the last three months. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.